Profile data is unavailable for this security.
About the company
AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology, which include Humira, Skyrizi and Rinvoq; oncology, which include Imbruvica, Venclexta/Venclyxto, Epkinly and Elahere; aesthetics products, which include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience, which include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy and Qulipta; eye care, which consists of Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. It offers NX-13, a first-in-class, oral NLRX1 agonist, for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). It also offers CEL383, a first-in-class anti-TREM1 antibody, for the treatment of inflammatory bowel disease.
- Revenue in USD (TTM)54.40bn
- Net income in USD5.95bn
- Incorporated2012
- Employees50.00k
- LocationAbbVie Inc1 N Waukegan RdNORTH CHICAGO 60064United StatesUSA
- Phone+1 (847) 932-7900
- Fax+1 (302) 655-5049
- Websitehttps://www.abbvie.com/
Mergers & acquisitions
| Acquired company | ABBV:NYQ since announced | Transaction value |
|---|---|---|
| Cerevel Therapeutics Holdings Inc | 14.80% | 8.62bn |
| ImmunoGen Inc | 19.83% | 10.22bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer Inc | 55.09bn | -288.00m | 159.91bn | 88.00k | -- | 1.73 | 25.44 | 2.90 | -0.0608 | -0.0645 | 9.71 | 16.28 | 0.2644 | 1.59 | 4.73 | 626,056.80 | -0.1219 | 8.20 | -0.1498 | 10.40 | 70.45 | 69.34 | -0.461 | 22.68 | 0.7784 | -- | 0.429 | 60.11 | -41.70 | 7.46 | -93.20 | -7.94 | 12.21 | 3.82 |
| Amgen Inc | 29.53bn | 3.76bn | 166.84bn | 26.70k | 44.44 | 33.22 | 20.02 | 5.65 | 7.00 | 7.00 | 54.97 | 9.36 | 0.3251 | 1.45 | 4.72 | 1,106,067.00 | 4.14 | 10.36 | 5.09 | 13.06 | 66.38 | 75.41 | 12.74 | 26.51 | 0.9793 | 2.46 | 0.9273 | 59.54 | 7.09 | 3.49 | 2.52 | -4.36 | 8.54 | 10.04 |
| AbbVie Inc | 54.40bn | 5.95bn | 300.85bn | 50.00k | 50.74 | 37.57 | 20.48 | 5.53 | 3.36 | 3.36 | 30.69 | 4.53 | 0.3839 | 4.54 | 4.65 | 1,088,060.00 | 4.24 | 6.55 | 5.61 | 8.40 | 66.30 | 69.74 | 11.04 | 16.46 | 0.8339 | 8.95 | 0.9019 | 111.46 | -6.44 | 10.65 | -59.09 | -3.44 | 4.02 | 10.52 |
| Merck & Co Inc | 61.40bn | 2.31bn | 323.95bn | 72.00k | 143.37 | 8.03 | 52.38 | 5.28 | 0.8921 | 0.8921 | 24.25 | 15.94 | 0.5748 | 2.50 | 5.64 | 852,805.60 | 2.17 | 7.70 | 2.81 | 10.29 | 74.85 | 72.26 | 3.78 | 15.03 | 0.9935 | 20.19 | 0.4584 | 89.55 | 1.40 | 7.29 | -97.49 | -43.80 | 8.12 | 8.26 |
| Johnson & Johnson | 85.65bn | 17.07bn | 352.43bn | 131.90k | 21.49 | 5.03 | 14.62 | 4.11 | 6.81 | 15.21 | 34.30 | 29.09 | 0.4656 | 2.15 | 5.47 | 649,340.40 | 9.28 | 8.93 | 13.19 | 11.96 | 69.57 | 68.17 | 19.93 | 18.86 | 0.9363 | -- | 0.3245 | 71.25 | 6.46 | 0.8622 | -18.59 | -2.72 | 4.36 | 5.83 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 162.36m | 9.20% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 92.80m | 5.26% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 77.97m | 4.42% |
| Capital Research & Management Co. (International Investors)as of 31 Mar 2024 | 48.10m | 2.72% |
| Geode Capital Management LLCas of 31 Mar 2024 | 37.49m | 2.12% |
| JPMorgan Investment Management, Inc.as of 31 Mar 2024 | 31.63m | 1.79% |
| Capital Research & Management Co. (Global Investors)as of 31 Mar 2024 | 31.30m | 1.77% |
| Charles Schwab Investment Management, Inc.as of 31 Mar 2024 | 22.72m | 1.29% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 20.84m | 1.18% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 18.75m | 1.06% |
